ORYZON is a publicly listed, clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics, focusing on personalized medicine for disorders of the central nervous system (CNS), oncology, and hematology
ORYZON is a publicly listed, clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics, focusing on personalized medicine for disorders of the central nervous system (CNS), oncology, and hematology.